The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Auckland City Hospital, Auckland

Northern Cancer Institute, St Leonards

Calvary Mater Newcastle, Newcastle

Mid North Coast Cancer Institute, Coffs Harbour

The Canberra Hospital, Garran

Icon Cancer Care, Brisbane

Capital and Coast District Health Board, Wellington

Roswell Park Cancer Institute, Buffalo

Fox Chase Cancer Center, Philadelphia

Virginia Cancer Specialists, Fairfax

Mount Sinai Comprehensive Cancer Center, Miami Beach

Centre Eugene Marquis, Rennes

Sarah Cannon Research Institute, Nashville

Vanderbilt University Medical Center, Nashville

Hospital Clínico Universitario de Valencia, Valencia

Texas Oncology, Dallas

Texas Oncology, Tyler

Rocky Mountain Cancer Centers, Denver

Pinnacle Oncology Hematology, Scottsdale

Cedars Sinai Medical Center, Los Angeles

Institut Gustave Roussy, Paris

Beth Israel Deaconess Medical Center, Boston

Westmead Hospital, Parramatta

Prince of Wales, Randwick

Monash Health, Clayton

Peter MacCallum Cancer Centre, Melbourne

Linear Clinical Research Ltd, Nedlands

Hospital Universitario Vall d'Hebrón, Barcelona

Sarah Cannon Research Institute, London